Jan 28, 2021 · 41m · we-live-to-build
The Patent Pending Secret That Adds $1M to Your Startup Valuation
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of the 'We Live to Build' podcast, host Sean Weisbrot interviews patent agent Dr. Devorah Grazer on how early-stage startups can strategically leverage intellectual property, navigate USPTO filing procedures, boost enterprise valuation, and adapt to emerging technologies like AI.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Sean holds 16.1% of the talking time here. How this is scored →
speaking balance: gold is Sean, purple is the guest (3 minute bins)
Dr. Grazer gently deflects Sean's philosophical question about AI sentience by steering the conversation back to existing case law requiring human authorship.
Hardest push from Sean ▶ 36:29 Sean challenges human-exclusive intellectual property rightsSean humorously pushes back against the legal doctrine excluding non-human creators by calling human-only copyright laws speciesist.
Biggest teaching moment ▶ 20:42 Grazer highlights the critical US vs international publication ruleDr. Grazer provides crucial legal distinction showing how public marketing triggers an immediate foreign patent bar while US law grants a one-year grace window.
Sean holds their own ▶ 27:51 Sean contextualizes patent systems against Industry 4.0 evolutionSean synthesizes technological history from the Industrial Revolution through modern AI to question how bureaucratic state institutions can keep pace.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Sean as informed peer | Guest teaching | Guest disagreement | Sean pushing back | Why |
|---|---|---|---|---|---|---|
| We Live to Build Show Bumper and Mission Statement | 2 | 5 | 1 | 0 | Sean introduces the podcast and asks Dr. Grazer about her background and the outcome of the Human Genome Project patent battles. Dr. Grazer explains how courts determined pure genetic material is unpatentable, educating Sean on biological IP law. | |
| Defining Patents: Legal Monopolies, History, and Disclosure Requirements | 1 | 6 | 0 | 0 | Sean asks foundational questions regarding what patents are and what types exist. Dr. Grazer delivers an informative breakdown of legal monopolies, historical guild secrecy, and utility versus design patents. | |
| The Territorial Nature of Global Patents | 1 | 7 | 0 | 0 | Sean inquires why there is no single international patent office and what the US filing workflow entails. Dr. Grazer walks through the territorial nature of patent treaties, patentability searches, claim drafting, and USPTO examiner negotiations. | |
| DIY Filing vs. Professional Patent Agents: Costs, Risks, and Timelines | 2 | 7 | 0 | 0 | Sean asks about the cost and timeline differences between self-filing and hiring a registered agent or attorney. Dr. Grazer highlights the precision of legal language, provisional applications, and the major financial and validity risks of DIY filing mistakes. | |
| USPTO Examination Backlogs and Claim Strategy | 2 | 7 | 0 | 0 | Sean asks about examination wait times and the pros and cons of patenting for startups. Dr. Grazer explains USPTO backlogs, uses a property fence analogy for claim scope, and notes that a pending patent application typically adds one million dollars to a startup valuation. | |
| Strategic Business Applications of Patents and Channel Sales Defense | 2 | 7 | 0 | 0 | Sean prompts Dr. Grazer to explain commercial drawbacks and optimal filing timelines. Dr. Grazer clarifies that US law offers a one-year post-publication grace period, whereas international jurisdictions require absolute novelty prior to public disclosure. | |
| Understanding Patent Trolls, Non-Practicing Entities, and Injunction Limits | 2 | 6 | 0 | 0 | Sean asks Dr. Grazer to define patent trolls and asks what key topics founders overlook. Dr. Grazer breaks down non-practicing entities and preliminary injunction legal standards, emphasizing why early proactive IP planning is critical. | |
| KISS Platform and Agile Competitive Intelligence with iSearch.ai | 2 | 4 | 0 | 0 | Sean asks about the unique selling proposition of Dr. Grazer's software tool iSearch.ai and KISS Platform. Dr. Grazer describes how the platform democratizes agile competitive intelligence and patent analysis for early-stage innovators. | |
| Future of Intellectual Property: Patent Pools and FRAND Licensing | 3 | 7 | 0 | 0 | Sean connects historical government origins with rapid modern technological shifts under Industry 4.0. Dr. Grazer responds by illustrating how modern patent pools and telecommunications FRAND licensing prevent market monopolization. | |
| Open Source, Defensive Patent Pledges, and Industry Non-Aggression | 3 | 6 | 1 | 0 | Sean asks if any industry has collectively boycotted patents. Dr. Grazer explains that while open-source licensing and corporate pledges like Tesla and Twitter exist, complete industry-wide non-aggression pacts remain largely non-existent. | |
| Artificial Intelligence in Patent Law: Authorship, Inventorship, and Ethics | 3 | 6 | 1 | 1 | Sean inquires whether AI must be deemed sentient to own patents, to which Dr. Grazer cites legal precedent from the monkey selfie case restricting inventorship to humans. Sean playfully objects to human-exclusive copyright frameworks. | |
| The Fundamentals of Patent Licensing and Business Agreements | 2 | 5 | 0 | 0 | Sean asks about the mechanics of patent licensing and recent business lessons. Dr. Grazer clarifies that licensing agreements are commercial contracts governed by overarching business goals, sharing how COVID forced agile operational pivots. |